Programme: Molecular Biology

Permanent URI for this collectionhttp://itsupport.cu.edu.ng:4000/handle/123456789/28780

Here you will find works strictly related to Molecular Biology

Browse

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Frequency Of BRCA1 Polymorphisms (rs799917 and rs1799966) Among Nigerian Breast Cancer Patients
    (Covenant University Ota, 2025-03) OGUNNIYI, OLUWABUSAYO BUNMI; Covenant University, Dissertation
    Breast cancer (BCa) is the most diagnosed malignancy among women worldwide, with an estimated 2.3 million new cases and 666,103 deaths recorded in 2022. In Nigeria, BCa remains the leading cause of cancer-related mortality among women, accounting for 32,278 (25.3%) new cases and 16,322 (20.5%) deaths in 2022. Breast cancer gene 1 (BRCA1) is a tumour suppressor gene involved in DNA damage repair, cell cycle regulation, and maintenance of genome stability. Studies suggest that genetic factors, such as Single Nucleotide Polymorphism (SNPs) in the BRCA1 genes, play a pivotal role in the development of cancers. The BRCA1 gene harbors specific SNPs within its coding sequence, including rs799917 and rs1799966. These SNPs interfere with the interaction between BRCA1 mRNA and miR-638, significantly decreasing BRCA1 expression among individuals carrying these variants. Several studies have reported correlations between BRCA1 polymorphisms rs799917 and rs1799966 with the risk of BCa. However, this relationship remains controversial. This study assesses the frequency of BRCA1 rs799917 and rs1799966 polymorphisms and their association with BCa in Nigeria. The case-control study included 500 BCa patients and 200 paired healthy controls. TaqMan genotyping assay was used to determine the genotypes of rs799917 and rs1799966 polymorphisms. Using logistic regression and Pearson's chi-square test, a statistically significant difference (p < 0.05) was identified in the genotype frequencies. The G allele of rs799917(p= 0.017; OR: 1.39) showed significant associations with the risk of breast cancer in Nigeria and, while globally reported as the wild-type allele, is observed as the variant allele in our population. The C Allele of rs1799966 confers a protective risk against breast cancer. Further study should focus on functional genomics to evaluate the interaction between miR-638 and the mRNA in individuals carrying this SNP, particularly in the Nigerian population. Keywords: breast
  • No Thumbnail Available
    Item
    PHYTOCHEMICAL AND BIOCHEMICAL EVALUATION OF FORMULATED ANTIDIABETIC HERBAL TEA FROM Vitex doniana and Spondias mombin
    (Covenant University, Ota, 2026-07) KAYODE, Oyinlola Deborah; Covenant University, Dissertation
    This study formulated and evaluated two antidiabetic herbal tea formulations from the underutilised Nigerian medicinal plants Vitex doniana and Spondias mombin. Formulation F1 was Vitex doniana-dominant, while F2 was Spondias mombin-dominant, with Zingiber officinale and Mentha spicata incorporated as functional adjuncts. The formulations were assessed for phytochemical composition, antioxidant capacity, in-vitro carbohydrate-enzyme inhibitory activity, proximate composition, and antimicrobial activity. The formulations were subsequently evaluated in STZ-induced diabetic Wistar rats at 200, 400 and 600 mg/kg for antidiabetic activity and toxicological effects. Qualitative screening detected alkaloids, carbohydrates, flavonoids, tannins, phenols, steroids and coumarins in both formulations, while saponins, terpenoids and cardiac glycosides were not detected. F1 recorded higher total phenolic, flavonoid and tannin contents, whereas F2 had higher alkaloid content. GC-MS confirmed 9-octadecenamide, (Z)- as the predominant library-matched compound in both formulations. Both formulations demonstrated concentration-dependent antioxidant and α-amylase/α-glucosidase inhibitory activities, with F1 generally showing stronger in-vitro performance. Proximate analysis showed higher crude fibre in F1 and higher protein and carbohydrate contents in F2. Microbial counts were low in both formulations, and both exhibited antimicrobial activity against the test organisms. In vivo, F1 and F2 produced significant (p<0.05) reductions in blood glucose concentration across the treatment period, with improvements also observed in several haematological, liver, kidney and lipid-profile parameters. No observable morbidity, mortality or behavioural abnormalities were recorded, and the treatment groups did not show a statistically demonstrated adverse effect on final body weight relative to the diabetic control. Overall, the findings indicate that both formulations possess promising antidiabetic and antioxidant potential with a generally favourable short-term safety profile, while formulation ratio influenced the magnitude and pattern of the observed biological responses